TerrAscend Catches the Rescheduling Wave — and a Cash Machine Is Already Running

Medical-cannabis rescheduling, a new CFO and a lean Northeast footprint put this $332M MSO ahead of a regulatory re-rating the market hasn't priced.

TSND.TO · Earnings Call · 2026-05-07

The regulatory moment arrives

TerrAscend's Q1 2026 call had one dominant theme: the federal rescheduling of medical cannabis. Executive Chairman Jason Wild called it "a monumental inflection point," and unlike the endless "reform is coming" language of prior calls, this time the policy shift is real with a first-order balance-sheet consequence — the elimination of the 280E tax burden, which Wild said will "materially improve profitability, further strengthen our balance sheet and lower our cost of capital over time."

We see rescheduling as the first step to improving access to institutional capital over time and providing public multistate operators such as TerrAscend with an opportunity to uplist onto a U.S. exchange such as the NASDAQ or the NYSE, which we view as an important driver of liquidity and ultimately long-term value creation.
Jason Wild, Executive Chairman · 2026-05-07

The phrasing is telling. For a company trading at roughly a $332M market cap, the path to a U.S. listing and cheaper capital isn't abstract ambition — it directly reshapes the equity. On M&A, Wild noted that targets are now "looking at our stock as something that has a higher likelihood of being able to go public on a U.S. exchange in the next, say, 12 to 24 months" — “rescheduling is quietly repricing how sellers value TerrAscend's paper, not just its cash flows.” — Jason Wild, Executive Chairman · 2026-05-07

An operating engine already running

The macro cheerleading would ring hollow if the underlying business weren't working — but it is. Revenue from continuing operations totaled $65.5M, returning to year-over-year growth; gross margin held at 52.8%; adjusted EBITDA reached $17.4M (a 26.5% margin); and the quarter generated $7.8M of free cash flow, marking the 15th consecutive quarter of positive operating cash flow and the 11th of positive FCF. Cost discipline is visible in the numbers as well: “G&A expenses for the first quarter were $21.5 million or 32.8% of revenue compared to $22.8 million or 34.4% of revenue in the fourth quarter of 2025 reflecting disciplined cost management.” — Alisa Campbell, Senior Vice President of Finance · 2026-05-07

We have generated approximately $24.3 million in free cash flow in the past 4 quarters, supported by improved working capital management and tighter inventory discipline across the business... Given all this, I am more confident in my future than I have ever been.
Ziad Ghanem, President and Chief Executive Officer · 2026-05-07

That roughly 10% free-cash-flow yield is a line few small-cap MSOs get to say. It's also what lets management stay patient — restating a "disciplined" accretive acquisitions posture even as Michigan exits (about 85% of asset sales complete, proceeds going to debt paydown) and Ohio remains a one-store outpost awaiting the right terms. Core Northeast markets carried the quarter: New Jersey retail gained share with the integrated Union Chill dispensary, Maryland runs at an ~$75M annualized run rate with gross margins in the high-50s, and Pennsylvania posted a fourth straight quarter of year-over-year revenue growth — with six reactivated cultivation rooms already harvested, capacity can scale without incremental CapEx ahead of a potential adult-use conversion.

A new CFO and a brand-new tailwind

Two threads are genuinely new this quarter. First, the company installed a new CFO, Eric Jackson, recruited from large-scale retail and consumer businesses. Jackson's opening was characteristically optimistic: “I've had the opportunity to work in large-scale complicated retail operations with great brands. I believe TerrAscend is uniquely positioned with a focus on high-quality, high-growth markets and a proven record of strong financial performance.” — Eric Jackson, Unknown (likely an executive or senior leader, new team member) · 2026-05-07 Second, psychoactive hemp has crystallized as a distinct strategic lever. Wild argued it is "arguably our industry's largest competitor with none of our industry's regulatory and tax burdens," and that Q4 regulation of the estimated $20B–$30B psychoactive hemp market is "a strong additional tailwind for our sector" — effectively steering that consumer back toward the regulated channel. It's a thesis the broader market hasn't started pricing yet.

Running on its own wave

What stands out about TerrAscend relative to the wider tape is how decoupled it is. The market's editor-curated top keywords of recent quarters have been dominated by tariffs, AI data centers and tech supply chains — "Batch Zero," "tariff refund," "receptor occupancy." TerrAscend's equity, by contrast, is being driven by an idiosyncratic, regulatory catalyst in cannabis. Prior calls set the table for exactly this moment — Ziad on Pennsylvania: “if the President reschedule cannabis at a federal level, then that would be the catalyst that will flip Pennsylvania almost immediately, in my opinion.” — Ziad Ghanem, President and Chief Executive Officer · 2025-11-06 And on valuation discipline: “when we look at dispensaries in Pennsylvania, we're still valuing them like their medical dispensaries. Once we have some type of dates certain launch for adult use... the multiples will work better.” — Jason Wild, Executive Chairman · 2025-03-06 The gap between what this call implies — tax relief, a possible uplist, accretive M&A, adult-use optionality in Pennsylvania — and a ~$332M market cap is the whole story. This is a genuine, company-unique inflection: a regulatory milestone the market is still digesting, layered on a business that has quietly become a cash generator across its core Northeast states. If rescheduling delivers even a portion of the retroactive tax relief management hinted at, the upside remains meaningful and still largely unpriced.